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Muriel Elhai1,2, Gilles Chiocchia3, Carmen Marchiol4, Franck Lager4, Gilles Renault4, Marco Colonna5, Guenter Bernhardt6,
Yannick Allanore1,2 and Jérôme Avouac1,2*Abstract
Background: Genetic studies have pointed out that CD226 variants, encoding DNAM-1, could be associated with
susceptibility to rheumatoid arthritis. Therefore, we aimed to determine the influence of DNAM-1 on the development
of arthritis using the collagen-induced arthritis (CIA) mouse model.
Methods: CIA was induced in mice on a DBA/1 background, treated in parallel with a DNAM-1 neutralizing monoclonal
antibody, a control IgG and PBS, respectively. CIA was also induced in mice deficient for DNAM-1(dnam1−/−) and
control dnam-1+/+ mice on a C57/BL6 background. Mice were monitored for clinical and ultrasound signs of
arthritis. Histological analysis was performed to search for inflammatory infiltrates and erosions. The Mann–Whitney U
test for non-related samples was used for statistical analysis.
Results: There was a non-significant trend for a less arthritic phenotype in mice receiving anti-DNAM-1 mAb at both
clinical, ultrasound and histological assessments. But, we did not observe any difference between dnam1+/+ and
dnam1−/− mice for incidence nor severity of clinical arthritis. Histological analysis revealed inflammatory scores similar
in both groups, without evidence of erosion. Collagen antibodies levels were similar in all mice, confirming
immunization with collagen.
Conclusion: Despite some clues suggesting a role of DNAM-1 in arthritis, these complementary approaches demonstrate
no contribution of CD226/DNAM-1 in the arthritic phenotype. These results contrast with previous studies showing a role
in vivo of DNAM-1 in some autoimmune disorders.
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Rheumatoid arthritis (RA) is a frequent disease leading
to joint destruction, deformity, and disability. Biologics
have shown their efficacy in limiting joint destruction
and have dramatically improved the outcome of RA-
patients. However, some patients remain refractory or
become nonresponder to these treatments, underlining
the need in this context for new or complementary
therapeutic strategies [1-3].* Correspondence: jerome.avouac@cch.aphp.fr
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unless otherwise stated.The pathogenesis of RA is characterized by chronic in-
flammation and synovial infiltration of immune cells
[4,5]. It results from the combination of genetic suscep-
tibility genes and environmental factors [6]. Until now,
most of the susceptibility genetic factors identified are
involved in inflammatory response and autoimmunity
[7]. Furthermore, the majority of these genetic factors
was also associated with other autoimmune diseases,
which were not characterized by an arthritic phenotype,
underlining the concept of a shared genetic background
between autoimmune diseases [8-10].
Recently, a non-synonymous single nucleotide poly-
morphism (SNP) Gly307Ser (rs763361) in the CD226
gene, which encodes the DNAX accessory molecule 1
(DNAM-1), has been associated with multiple autoimmunehis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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membrane protein belonging to the immunoglobulin
supergene family of receptors. It is constitutively expressed
on the majority of CD4+ and CD8+ T cells, monocytes,
natural killer cells, platelets and a subset of B cells. It is in-
volved in the adhesion and co-stimulation of T cells in a
Th1 pathway [19]. Interestingly, there are accumulating evi-
dences suggesting a key role of T cells in the pathogenesis
of RA characterized by a marked shift toward Th1 and
Th17 phenotypes [20]. Furthermore, DNAM-1 was found
to be significantly expressed on CD4+CD28- T cells from
RA-patients and to be involved in co-stimulation of these
cells [21]. Therefore, it remains to determine whether
CD226 Gly307Ser (rs763361) contributes specifically to the
expression of the arthritic phenotype in RA or does it just
reflect a common genetic background between auto-
immune diseases. For this purpose, we aimed to validate
in vivo this genetic susceptibility factor, using the collagen-
induced arthritis (CIA) model, which is a widely used
model for RA and has been important for understanding
RA pathogenesis [22-24]. This might also reveal patho-
physiological pathways leading to new potential therapeutic
targets. We combined a targeted molecular approach with
neutralizing anti-DNAM-1 monoclonal antibody (mAb)
and a gene inactivation strategy using mice lacking
DNAM-1 (dnam1−/−) in the CIA mouse model and
demonstrated that inhibition of DNAM-1 does not
have a direct influence on the development of inflam-
matory arthritis in mice.
Methods
Mice
DBA/1 mice were purchased from Janvier (Le Genest-St-
Isle, France). Dnam1−/− mice have been described else-
where [25]. C57/BL6 expressing DNAM-1 (dnam1+/+)
were also purchased from Janvier (Le Genest-St-Isle,
France). All mice were 6–8 weeks of age at the time of
experimentation, were fed standard rodent chow and
water ad libitum. To prevent from a cage effect, mice on
different background or with different treatments were
randomly assigned to each cage. The study was approved
by the Cochin institute committee on animal care and
its registered number is CEEA34.GC.052.12.
Induction of CIA
For DBA/1 mice an emulsion was formed by dissolving
2 mg/ml bovine native collagen II (CII) (MD BioSci-
ences, Zurich, Switzerland) overnight at 4°C in 10 mM
acetic acid and combining it with an equal volume of
complete Freund's adjuvant (CFA) emulsification (MD
BioSciences, Zurich, Switzerland). DBA/1 mice were
injected intradermally at three sites into the base of the
tail with a total of 100 μl emulsion containing 200 μg
CII emulsified in CFA. On day 21, an injection with CIIin incomplete Freund’s adjuvant (IFA) was repeated as a
booster [26]. CII solution and the emulsion with CFA or
IFA were always freshly prepared. In this model, arthritis
develops 20–30 days after the first collagen injection.
For C57/BL6 mice, the emulsion was formed by dis-
solving 4 mg/ml chicken CII overnight at 4°C in 10 mM
acetic acid and combining it with an equal volume of CFA
emulsification (MD BioSciences, Zurich, Switzerland). The
booster was performed using the same protocol as for the
priming immunization [27,28]. In this model, arthritis
develops 50–60 days after the first collagen injection.
Effect of DNAM-1 in CIA
To investigate whether prophylactic treatment with an
anti-DNAM-1 neutralizing monoclonal antibody (mAb)
might protect from the development of CIA, arthritis
was induced in three groups of 7 DBA/1 mice (all males,
6–8 weeks old). In parallel, mice were treated intraperi-
toneally with the neutralizing anti-DNAM-1 mAb TX42
(rat IgG2a), at a concentration of 1.6 mg/ml, initially at a
dose of 400 μg at day-1, then 200 μg every 5 days for 3
weeks, as previously described [29,30]. This antibody has
been shown to inhibit DNAM-1 binding to its ligands
CD155 and CD112 and inhibits activation of T cells
in vitro [31]. Two control groups were treated for three
weeks from day-1 with control rat IgG (MP Biomedicals)
and PBS, respectively.
To determine whether DNAM-1 deficient mice were
protected from CIA, arthritis was induced in 7 dnam1+/+
and 5 dnam1−/−. All dnam1+/+ and dnam1−/−mice were
males of 6–8 weeks old.
Evaluation of arthritis
Clinical assessment of arthritis
Mice were monitored for evidence of arthritis in their
four paws using a blind procedure, by two examinators
(G.C. and M.E.) and a clinical score based on disease se-
verity was given for each mouse. Clinical assessment was
performed two to three times per week, for up to 60
days in C57/BL6 mice and 35 days in DBA/1 mice as
previously described [32]. Briefly, the date of disease on-
set was recorded, and the clinical severity of each joint
or group of joints (toes, tarsus, ankle, wrist and fingers)
was graded as follows: 0 (normal), 1 (swelling or focal
redness of finger joints), 2 (mild swelling), 3 (severe
swelling) or 4 (necrosis). Clinical scores of each joint
(graded 0–4) were summed to yield the arthritic score
and the severity of CIA was expressed as the mean score
observed on a given day, as the mean of the score
reached by mice during the experiment and as the mean
of the maximal arthritic score reached by each mouse.
The maximum score reached for each of the 10 joints
was 4, so the maximum score of clinical arthritis reached
for a single mouse on a given day was 40. Incidence of
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ing swelling of any paws (score > 1) with the number of
total mice.
Ultrasound methodology
Animal preparation Mice were sedated using 1.5% iso-
fluorane in air (Minerve équipement vétérinaire, Esternay,
France). They were attached on the heating pad in a supine
position [33]. Hairs were removed from the knee and ankle
using depilatory cream.
Evaluation of arthritic joints by ultrasound This
evaluation was performed in collaboration with the
Small Animal Imaging Facility, which developed the
ultrasound (US) examination in arthritic mice. Mice
were monitored for evidence of arthritis in their knees,
ankles, tarsus and toes by a blinded examinator (C.M),
as previously described [34]. US examinations were per-
formed using Ultrasound biomicroscope UBM (VEVO770,
Visualsonics) either in B mode or in Doppler mode. A 60
MHz probe (RMV708) was used for optimal spatial reso-
lution (with axial resolution up to 30 mm), and attached to
an articulated arm (MP-Tec AG, Veltheim, Switzerland).
The position was kept by tightening the articulated arm.
Power Doppler imaging settings were defined as follows:
the scan speed was set to 2 mm/s, the wall filter to 2.5
mm/s, the number of pulses to two radio-frequency cycles.
Emitted power (ranging from 10 to 50%) and colour prior-
ity over grey scale were adjusted to allow visualisation of
the vessels and remove the colour signal at the skin/tissue
interface (Doppler artefacts). In B-mode images, each joint
or group of joints was coted according to five different
grades. Vascularisation was scored by the operator accord-
ing to four different grades, depending upon the percentage
of coloured pixels in the joint area, i.e. Grade 0: no detect-
able power Doppler signal; grade 1: one to two small colour
Doppler areas (about 0.1 × 0.1 mm); grade 2: two to four
medium colour Doppler areas (about 0.15 × 0.15 mm);
grade 3: more than four large colour Doppler areas (over
0.2 × 0.2 mm).
On C57/BL6 mice, there was a power Doppler back-
ground level, which was not considered as pathological,
since it was observed on naive C57/BL6 mice.
Six C57/BL6 and DBA/1 non-immunized mice (males of
6–8 weeks of age) were assessed as controls at B-mode and
Doppler.
Histological assessment of arthritis
At the end of the experiment, i.e. day 35 in DBA/1 mice
and day 62 in C57/BL6 mice, corresponding to the de-
crease in signs of arthritis, mice were killed by cervical
dislocation, the paws of the mice were removed, fixed,
decalcified and paraffin embedded. At least four serialsections were cut from each paw to ensure extensive
evaluation of the arthritic joints. Sections (5 μm) were
stained with hematoxylin and eosin and examined to
search for inflammation, pannus formation, and cartilage
and bone damage. All images were captured with a
Nikon Eclipse 80i microscope (Nikon, Badhoevedorp,
Netherlands) equipped with a DSP 3CCD camera (Sony,
Tokyo, Japan). The histological severity of the arthritis
was scored on a scale of 0–3 for synovitis (synovial prolif-
eration, inflammatory cell infiltration) and erosions by two
examinators (G.C. and M.E.), blinded to the diagnosis [35].
Assessment of DNAM1+T cells and T cell infiltrates
We aimed to quantify T cell infiltrates and DNAM1+T
cells in arthritic joints from mice treated with anti-
DNAM1, PBS or control IgG. We performed immuno-
fluorescent staining in paws sections from 4 mice from
each group (i.e. treated with anti-DNAM1, control IgG
and PBS). Sections were deparaffinized, followed by anti-
gen retrieval with Tris/EDTA/Tween, incubation with
5% bovine serum albumin in phosphate buffered saline
for 1 hour to block non-specific binding. The number of
T cells in the infiltrate was detected by staining for one
hour at 4°C with polyclonal rabbit anti-mouse antibodies
for CD3 (Abcam, Cambridge, UK). Alexa Fluor® 488
Goat Anti-rabbit antibodies (Life Technologies Saint
Aubin, France) was used as secondary antibody for one
hour at room temperature. For co-staining experiments,
the expression of DNAM-1 and the number of T cells
were detected by staining overnight at 4°C with poly-
clonal rabbit anti-mouse DNAM-1 antibody (Abcam,
Cambridge, UK) and monoclonal rat anti-mouse anti-
bodies for CD3 (Abcam, Cambridge, UK), respectively.
Alexa Fluor® 488 Goat Anti-rat and Alexa Fluor® 594
Goat Anti-rabbit antibodies (Life Technologies Saint
Aubin, France) were used as secondary antibody for one
hour at room temperature. Nuclei were stained using
DAPI. Slides were then mounted coverslip with a drop
of mounting medium and stored in the dark at +4°C
until analyze. All images were captured on a Zeiss Axio
Observer Z1 microscope with a dry × 40 objective and
CoolSNAP HQ2 CCD camera. Four mice were used for
this experiment and 4 pictures were taken by mouse.
The number of CD3+ and DNAM1+CD3+ cells were
counted by two examinators blinded to the treatment.
Detection of anti-CII Ab by ELISA
Anti-CII antibodies were detected in the serum of mice.
Mice were bled by cardiac puncture at the time of death,
just after cervical dislocation. Sera were stored at – 20°C
until use. ELISA assays were performed for the detection
of Abs to CII by coating 96-well flat-bottom plates with
50 μl of CII (2 mg/ml in PBS) overnight at 4°C. The
wells were then blocked by 2-h incubation at 4°C with
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serial twofold dilutions (beginning at 1/1600 dilution) of
mouse sera in PBS containing 2% BSA and 0.1% Tween-
20 were applied and incubated overnight at 4°C. Three
washes in PBS/0.05% (v/v) Tween-20 were applied be-
tween all steps. Polyclonal rabbit anti-mouse labeled
with horseradish peroxidase (HRP) (Dako, Glostrup,
Danmark)(50 μl) diluted in PBS containing 2% BSA and
0.1% Tween-20 were next applied for 2 h at room
temperature (dilution 1:200). Five washes in PBS/0.05%
(v/v) Tween-20 were applied between all steps. Anti-
bodies were detected by incubation with TMB (3,3', 5,5’-
tetramethylbenzidine) (Sigma, Lyon, France) substrate
for 45 minutes in the dark. Optical density was mea-
sured at 450 nm. A standard curve was created for each
assay by including serial dilutions of a reference sample
obtained from the pooled sera of all immunized mice on
each plate. The reference sample was arbitrarily assigned
an antibody concentration of 1 AU/mL. Antibody con-
centrations for each serum sample were obtained by ref-
erence to this standard curve and were expressed in
relative titer to this reference sample. We also tested
control sera of non-immunized mice to calculate a posi-
tivity threshold.
Statistical analysis
All data analyses were performed using Graph Pad Prism
6.01 (2012). Data were presented as median (+/− IQR)
for continuous variables and numbers (percentages) for
categorical variables. The Mann–Whitney U test for
non-related samples was used for statistical analysis.
Correlation between US and clinical assessments for
ankle, tarsus and toes was assessed using Spearman rank
correlation coefficient (rho). A p-value of less than 0.05
was considered statistically significant.
Results
Anti-DNAM-1 mAb does not protect from the
development of CIA
The mouse model of CIA was used to evaluate the anti-
arthritic potential of DNAM-1 inhibition in vivo using a
neutralizing anti-DNAM-1 mAb. First evidence of arth-
ritis appeared at day 19 post-immunization. Clinical evi-
dence of arthritis (defined by at least one joint with a
score > 1) was observed in 5/7 (71%) mice treated with
anti-DNAM-1 mAb, 6/7 (86%) mice treated with control
IgG and 7/7 (100%) mice injected with PBS (p = 0.51
and 0.13) (Figure 1a). Incidence of arthritis increased in
the three groups during the time, but was less important
in mice injected with anti-DNAM-1 mAb (Figure 1b).
Median of the mean [± IQR] clinical score was 1.9 [0.2-8.1]
in mice receiving anti-DNAM-1, 9.4 [2.8-12.1] in those
treated with control IgG (p = 0.13) and 5.0 [3.9-13.2] in
mice treated with PBS (p = 0.17) (Figure 1c).Consistent with these previous results, the maximal
score had a non-significant trend to be lower in mice re-
ceiving anti-DNAM-1 mAb (p = 0.37 and 0.25 versus
mice injected with control IgG and PBS, respectively)
(Figure 1d). The day of the maximal score was similar in
the three groups (32nd day in the first two groups and
34st day in the latter; p = 0.67 and 0.78 versus control
IgG and PBS, respectively) (Figure 1b).
To better evaluate the difference between the three
groups, we combined an US approach, which allows an
accurate assessment of both synovitis in B-mode and in-
flammatory activity with Doppler. US was consistent
with our clinical assessment, as it revealed a non-
significant trend for lower scores in B-mode assessment
in mice treated with anti-DNAM-1(p = 0.25) (Figure 2a
and b). Moreover, Doppler demonstrated a less inflamma-
tory activity in mice receiving anti-DNAM-1 as compared
to those treated with control IgG or PBS, but it did not
reach significance (p = 0.43 and p = 0.41, respectively)
(Figure 2c and d).
In all non-immunized mice, both B-mode and Doppler
scores were equal to 0.
Collagen antibodies levels were similar in the three
groups (p = 0.75 and p = 0.62, respectively), confirming
the immunization with CII (Figure 3a).
Histological analysis revealed extensive inflammatory
infiltrates in the synovium, without evidence of bone
damage in all groups (Figure 3b). Inflammatory scores
were not significantly different across the three groups,
despite a trend for lower scores in those receiving anti-
DNAM-1 (p = 0.35 and p = 0.10 versus mice injected
with control IgG and PBS, respectively) (Figure 3c). To
further assess the effect of anti-DNAM1 antibody, we
quantified T cell infiltrates and DNAM1+T cells in each
group of mice. We observed a significant reduction of
the number of infiltrating T cells and the number of T
cells expressing DNAM-in mice treated with anti-
DNAM1 antibody as compared to mice injected with
control IgG and PBS (Additional file 1: Figure S1).
DNAM-1 mAb was administered without serious ad-
verse events for 3 weeks. No substantial changes were
observed among mobility, activity, and comportment be-
tween mice treated with anti-DNAM-1 mAb or control
IgG. Moreover, weight loss was <10% and no significant
reduction of the food consumption was observed.
Although not significant, our results suggested a
trend toward a less arthritic phenotype in mice treated
with anti-DNAM-1 mAb. However, the molecular tar-
geted strategy may be characterized by an incomplete
blockade of the pathway targeted, unlike the gene in-
activation strategy. Therefore to better assess the effect
of invalidation of DNAM-1 in prevention of CIA, we
decided to use mice deficient for DNAM-1, in which
the pathway is completely blocked. We used these mice
Figure 1 Anti-DNAM-1 monoclonal antibody does not protect from the development of collagen-induced arthritis at clinical assessment.
(a) Clinical evidence of arthritis with redness and swelling of the paws involving tarsus, ankle and toes in the three groups: the first group was treated
with anti-DNAM-1 monoclonal antibody (n = 7); the second was treated with control IgG antibody (n = 7) and the third with PBS (n = 7). Pictures were
taken at day 30. (b) Clinical score similarly increased in the three groups from the injection to the end point. This score had a trend to be lower in the
group injected with anti-DNAM-1 without significance. The blue curve represents the scores obtained in mice treated with AC anti-DNAM1 (n = 7), the
red one those obtained in mice receiving control IgG (n = 7) and the green one the scores in mice treated with PBS (n = 7). (c and d) Median of the
mean clinical score and of the maximal score were not significantly different between mice injected with anti-DNAM-1 and those treated with control
IgG and PBS, but there was a trend for lower score in mice injected with anti-DNAM-1. Values are the median ± IQR.
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ground [29].
Mice deficient for DNAM-1 are not protected from CIA
To further evaluate the role of DNAM-1 in CIA, 5
dnam1−/− mice and 7 control dnam1+/+ mice were im-
munized with CII. First evidence of arthritis appeared atday 38. All, 7/7 (100%) dnam1+/+ and 4/5 (80%)
dnam1−/− mice developed arthritis (p = 0.22) (Figure 4a).
Incidence of arthritis increased similarly in both groups
during the time (Figure 4b).Median of the mean [± IQR]
clinical score was 6.0 [4.6-8.0] in dnam1+/+ mice versus
4.9 [3.6-7.1] in dnam1−/− mice (p = 0.60) (Figure 4c).
Consistent with these results, maximal clinical score
Figure 2 Anti-DNAM-1 monoclonal antibody does not protect from the development of collagen-induced arthritis at US assessment. (a)
Examples of picture of the knees in B-mode assessment in mice injected with anti-DNAM1 (n = 7) (B-mode score = 0.5), those treated with control IgG
antibody (n = 7) (B-mode score = 1.5) , those injected with PBS (n = 7) (B-mode score = 1.5) and control non-immunized mice (n = 6) (B-mode score = 0).
(b) B-mode score was not significantly different between the three groups, despite a trend for lower scores in mice injected with anti-DNAM-1. (c)
Examples of picture of inflammatory synovitis at Doppler assessment in tarsus of the three groups of mice (Doppler score = 1 in mice injected
with anti-DNAM-1, whereas it was equal to 2 in the other groups). Example of Doppler assessment in tarsus of non-immunized mice (Doppler
score = 0 in all 6 non-immunized mice). To note, there are artefacts signals Doppler on bone. (d) Doppler score was not significantly different
between the three groups, despite a trend for lower scores in mice injected with anti-DNAM-1.Values are the median ± IQR.
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(Figure 4d).The day of the maximal score was similar in
both groups (53rd day in dnam1−/− mice and 56st day in
dnam1+/+ mice, p = 0.78) (Figure 4b).
We combined a B–mode US assessment to better
evaluate arthritis in the mice and observed similar scores
in dnam1+/+ mice (5.2 [4.2-7.2] and dnam1−/− mice
(5.7 [4.6-9.3] in B-mode (p = 0.53) (Figure 5a and b). Of
interest, Doppler, which is an accurate tool to measure in-
flammatory activity in cases of arthritis, did not demon-
strate any difference between dnam1+/+ and dnam1−/−
mice (scores: 4.2 [3.1-5.4] and 4.9 [4.0-6.5], respectively;
p = 0.53) (Figure 5c and d). In all non-immunized mice,
both B-mode and Doppler scores were equal to 0.
Collagen antibodies levels were also similar in dnam1+/+
and dnam1−/− mice (p = 0.88) (Figure 6a).
Histological analysis revealed mild inflammatory infil-
trates in the synovium, without evidence of bone damage
(Figure 6b). Inflammatory scores were low and not signifi-
cantly different in both groups (p = 0.79) (Figure 6c).Correlation between US and clinical assessments
We assessed correlation between US and clinical assess-
ments in both experiments, for the joints, which were
assessed by both methods (i.e. ankle, tarsus and toes)
and observed a high correlation (rho: 0.71; p<0.01).
Discussion
In the present study, we demonstrate that CD226/
DNAM-1 may be not a relevant target in RA, using an
in vivo approach in the CIA model. Despite several gen-
etic studies revealing that CD226 was a susceptibility
genetic factor for RA in different ethnic groups [11-18],
neither inactivation of DNAM-1 nor a molecular tar-
geted strategy using a neutralizing mAb against DNAM-
1 prevented from CIA. To assess rigorously the effect of
invalidation of DNAM-1, we used four different vali-
dated parameters (clinical score, US score, histological
assessment and collagen antibodies levels) [34]. All these
four parameters displayed the same results, demonstrat-
ing no significant effect of invalidation or neutralization
Figure 3 Anti-DNAM-1 monoclonal antibody does not protect from the development of collagen-induced arthritis at histological assessment.
(a) Collagen antibodies levels detected by Elisa in mice injected with anti-DNAM-1 antibody, control IgG antibody and PBS. A standard curve was created
for each assay by including serial dilutions of a reference sample obtained from the pooled sera of all immunized mice on each plate. The
reference sample was arbitrarily assigned an antibody concentration of 1 AU/mL. Antibody concentrations for each serum sample were
obtained by reference to this standard curve and were expressed in relative titer to this reference sample. Collagen antibodies levels are
similar in the three groups, confirming the immunization with collagen. (b) Examples of knee sections stained by hematoxylin-eosin revealing inflammatory
infiltrates (arrow) but no erosions in the three groups, i.e. treated with anti-DNAM-1 monoclonal antibody, treated with control IgG antibody and injected
with PBS. Bar: 100μm. (c) Inflammatory score at histological assessment had a no significant trend to be lower in mice injected with anti-DNAM-1 as
compared to those treated with control IgG and PBS. Values are the median ± IQR.
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arthrogenic effect of the antibody on its own, since we
did not observe any clinical arthritis in non-immunized
control mice treated with this mAb in a previous
project [29].
Until now, genetic approaches have revealed that
CD226 Gly307Ser (rs763361) polymorphism was signifi-
cantly associated with several different autoimmune dis-
eases and the risk of multiple autoimmune diseases[11-18,36-38]. There is increasing evidence suggesting
that autoimmune diseases share a genetic background
and that autoimmune phenotypes represent pleiotropic
outcomes of nonspecific disease genes [9,10,39]. Several
susceptibility genes for autoimmune diseases have been
identified without confirmation of their involvement in
the development of the pathogenic phenotype. There-
fore, it is crucial to proceed to their functional validation
in vivo. So far, the contribution of CD226/DNAM-1 to
Figure 4 Mice deficient for DNAM-1 are not protected from collagen-induced arthritis at clinical assessment. (a) Examples of picture of
clinical arthritis in paws from dnam1+/+ and dnam1−/− mice with redness and swelling of the paws involving tarsus, ankle and toes in both
groups. Pictures were taken at day 54. 7 dnam1+/+ and 5 dnam1−/− mice were used. (b) Clinical score similarly increased in dnam1+/+ and
dnam1−/− mice without significant difference. (c) Mean of the different clinical scores is not different between dnam1+/+ and dnam1−/− mice.
(d) Maximal clinical score is similar in dnam1+/+ and dnam1−/− mice. Values are the median ± IQR.
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demonstrated in vivo in some murine models [29,38,40].
In a murine model of multiple sclerosis, i.e. experimental
autoimmune encephalomyelitis, anti-DNAM-1 treat-
ment delayed the onset and reduced the severity of the
disease [40]. In a mouse model of acute graft-versus-
host disease (GVHD), invalidation of DNAM-1 and an
anti-DNAM-1 mAb were both associated with a milder
GVHD and prolonged survival [38]. Recently, our groupdemonstrated that inhibition of DNAM-1 significantly
ameliorated dermal fibrosis, in a murine model of sys-
temic sclerosis [29]. In all these murine models, the
blocking of DNAM-1 was associated with decreased
infiltration of T cells, suggesting that it could reflect a
general effect of DNAM-1 on inflammation rather that
an effect linked to a specific genetic susceptibility for the
autoimmune disease considered. Here we show that
blocking CD226/DNAM-1 has no effect in another T
Figure 5 Mice deficient for DNAM-1 are not protected from collagen-induced arthritis in B-mode. (a) Examples of picture of ankle
at ultrasound assessment in B-mode (B-mode score for the ankle = 1 in dnam1+/+ mice and 1.5 in dnam1−/− mice). Examples of ankle at
B-mode assessment in control non-immunized mice (n = 6) (B-mode score = 0). (b) B-mode score was similar in dnam1+/+ and dnam1−/−
mice. (c) Examples of picture of ankle at ultrasound assessment in Doppler (Doppler score for the ankle = 1 in dnam1+/+ mice and 1.5 in
dnam1−/− mice). Example of Doppler assessment in ankle of non-immunized mice (Doppler score = 0 in all 6 non-immunized mice). To note,
there are artefacts signals Doppler on bone. (d) Doppler score was not different between dnam1+/+ and dnam1−/− mice. Values are the
median ± IQR.
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in infiltrating T cells, consistent with what was observed
in the mouse models of dermal fibrosis [29]. This sug-
gests that other cells are involved in the physiopathology
of CIA. This also highlights that DNAM-1 may be impli-
cated in the development of a specific pathogenic
phenotype, such as dermal fibrosis, encephalomyelitis
and GVHD, but non RA.
In this report, we confirm that mice on a C57BL/6
background can develop clinical signs of arthritis with a
high incidence around 100%, using a modified proced-
ure. Incidence of arthritis in our study was much higher
than in previous reports (60-70%) [27,28,41]. Severaldifferences may account for this discrepancy: first we
used a concentration of CII equal to 4 mg/ml instead of
2mg/ml, secondly we performed immunization only on
male mice and thirdly male were younger than in previous
studies. This slightly modified procedure (previously used
by our team (unpublished results)) could increase the inci-
dence of arthritis in C57/BL6 mice, but should be evaluated
in further studies. This is of interest, since most of the
knockout mice are on a C57/BL6 background. Nonetheless,
the severity of clinical arthritis was lower in C57/BL6 mice
than in DBA/1 mice, which is consistent with a previous
study [27]. In this report, we also confirmed that arthritis
develops later in mice on a C57/BL6 background (around
Figure 6 Mice deficient for DNAM-1 are not protected from collagen-induced arthritis at histological assessment. (a) Collagen antibodies
levels detected by Elisa. A standard curve was created for each assay by including serial dilutions of a reference sample obtained from the pooled
sera of all immunized mice on each plate. The reference sample was arbitrarily assigned an antibody concentration of 1 AU/mL. Antibody
concentrations for each serum sample were obtained by reference to this standard curve and were expressed in relative titer to this
reference sample. Collagen antibodies levels were similar in dnam1+/+ and dnam1−/− mice, confirming the immunization with collagen
in all mice. (b) Example of a knee section stained by hematoxylin-eosin revealing inflammatory infiltrates (arrow) but no erosions in a
dnam1+/+ mouse. Example of a tarsus section stained by hematoxylin-eosin revealing inflammatory infiltrates (arrow) but no erosions in a
dnam1−/− mouse. Bar: 100μm. (c) Inflammatory score at histological assessment was not significantly different in dnam1+/+ mice and
dnam1−/− mice. 7 dnam1+/+ mice and 5 dnam1−/− mice were used. Values are the median ± IQR.
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[27,28,41]. However, we observed a lower incidence and se-
verity at histological assessment with low inflammatory
scores in C57/BL6 mice than in DBA/1 mice.
US was proved to be a valuable method for evaluating
arthritic lesions in mice on a DBA/1 background [34].
Here we confirm these results and suggest that US could
also be used in other background, such as C57/BL6 with
preliminary results, revealing high concordance with
clinical analysis. Moreover, power Doppler allows visual-
izing and quantifying joint vascularization during the
course of the disease. Therefore, the ability of US in in-
vestigating arthritic lesions in C57/BL6 mice should be
evaluated in further studies.
Our study should be interpreted within its limitations.
First, we could not exclude an immunization of our mice
against this antibody. However, there were a significant
reduction of infiltrating T cells, especially those express-
ing DNAM-1, following treatment with anti-DNAM-1
mAb suggesting that the Ab was biologically effective on
these mice, despite no effect on the arthritic phenotype
was detected. Moreover, we did not observe any boneand cartilage erosions unlike previous publications and
induction of arthritis on the C57/BL6 background was
challenging [27,28,41]. However, there was evidence of
induction of arthritis with clinical signs of arthritis, in-
flammatory infiltrates at histology and production of CII
antibodies. Nevertheless, we can suggest using other
models, such as antigen-induced arthritis using mBSA or
K/BxN serum-induced arthritis, to confirm our results.
In addition, we could not assess the correlation between
clinical and US assessments for all joints, since some joints
were assessed only clinically (i.e. wrists and fingers),
whereas knees only were evaluated by US alone. However,
our results demonstrate a high correlation between clinical
and US evaluations for all joints investigated. Moreover, US
is an operator-dependent method and here the assessment
was only performed by one examinator. Nevertheless, this
was performed by a trained investigator, who developed this
strategy [34].
Conclusion
Inhibition of DNAM-1, a critical new genetic factor in
autoimmune disorders, does not prevent the
Elhai et al. Journal of Inflammation  (2015) 12:9 Page 11 of 12development of CIA, despite its efficacy in other models
of inflammatory diseases, such as bleomycin-induced fi-
brosis, encephalomyelitis and GVHD. This interesting
result suggests that DNAM-1 might be involved in the
development of a specific autoimmune phenotype and
not in all inflammatory diseases. It remains to assess the
efficacy of inhibition of DNAM-1 in vivo in other auto-
immune diseases, in which CD226 was identified as a
susceptibility genetic factor, such as type 1 diabetes and
systemic lupus erythematosus [11,13,36].
Additional file
Additional file 1: Figure S1. Treatment with anti-DNAM-1 monoclonal
antibody was associated with a decrease in infiltrating T cells and in T
cells expressing DNAM-1 (a) Representative pictures showing decreased T
cell infiltrates in mice injected with anti-DNAM-1 monoclonal antibody. T
cells are identified by CD3 staining (in green), whereas nuclei are stained
in blue. (b) Reduction of infiltrating T cells in the group of mice treated
with the monoclonal antibody against anti-DNAM-1 (n = 4), compared to
those treated with control IgG antibody (n = 4) and those injected with
PBS (n = 4). (c).The number of infiltrating T cells expressing DNAM-1 was
significantly lower in mice treated with the anti-DNAM1 monoclonal antibody
(n = 4) as compared to those receiving either control IgG (n = 4) either PBS
(n = 4). Values are the median ± IQR. **: p<0.01.
Abbreviations
CII: collagen II; CIA: collagen induced-arthritis; CFA: complete Freund's
adjuvant; DNAM-1: DNAX accessory molecule 1; GVHD: graft-versus-host
disease; IFA: incomplete Freund's adjuvant; mAb: monoclonal antibody;
RA: rheumatoid arthritis; SNP: single nucleotide polymorphism;
US: ultrasound..
Competing interests
All the authors declare to have no competing interests.
Authors’ contributions
Study conception and design: ME, G.C, M.C, G.B, Y.A, J.A. Acquisition of data:
M.E, G.C, C.M, F.L, G.R. Analysis and interpretation of data: M.E, G.C, C.M, G.R,
Y.A, J.A. All authors were involved in drafting the article or revising it critically
for important intellectual content, and all authors approved the final version
to be published.
Acknowledgements
We thank the Small Animal Imaging Facility INSERM U1016 (Didier Fradelizi),
the Histology Department, INSERM U1016 (Maryline Favier and Corinne
Lesaffre) and the Cochin Imaging facility (Pierre Bourdoncle) for excellent
technical assistance. We thank Melanie Piedavent and Manuel Friese for
providing us the monoclonal antibody anti-DNAM-1.
Grant supports
INSERM, Société Française de Rhumatologie, Fondation pour la recherche
Médicale, Arthritis Foundation.
Author details
1Rheumatology A department, Cochin Hospital, Paris Descartes University,
Sorbonne Paris Cité, 27 rue du Faubourg Saint Jacques, 75014 Paris, France.
2Cochin Institut, INSERM U1016, UMR 8104, Team ATIP/AVENIR, Paris
Descartes University, Paris, France. 3Inserm U987, Université
Versailles-Saint-Quentin, Montigny-Le-Bretonneux, France. 4Small Animal
Imaging Facility, Paris Descartes University, INSERM U1016, Institut Cochin,
Sorbonne Paris Cité, Paris, France. 5Department of Pathology and
Immunology, Washington University School of Medicine, St Louis, USA.
6Institute of Immunology, Hannover Medical School, Hannover, Germany.Received: 10 June 2014 Accepted: 26 January 2015
References
1. Blom M, Kievit W, Fransen J, Kuper IH, den Broeder AA, De Gendt CMA, et al.
The reason for discontinuation of the first tumor necrosis factor (TNF) blocking
agent does not influence the effect of a second TNF blocking agent in patients
with rheumatoid arthritis. J Rheumatol. 2009;36(10):2171–7.
2. Tak PP, Kalden JR. Advances in rheumatology: new targeted therapeutics.
Arthritis Res Ther. 2011;13 Suppl 1:S5.
3. Upchurch KS, Kay J. Evolution of treatment for rheumatoid arthritis.
Rheumatol Oxf Engl. 2012;51 Suppl 6:vi28–36.
4. Boissier MC. Cell and cytokine imbalances in rheumatoid synovitis. Jt Bone
Spine Rev Rhum. 2011;78(3):230–4.
5. Fournier C. Where do T cells stand in rheumatoid arthritis? Jt Bone Spine
Rev Rhum. 2005;72(6):527–32.
6. Dieudé P. Rheumatic diseases: environment and genetics. Jt Bone Spine Rev
Rhum. 2009;76(6):602–7.
7. Bax M, van Heemst J, Huizinga TWJ, Toes REM. Genetics of rheumatoid
arthritis: what have we learned? Immunogenetics. 2011;63(8):459–66.
8. Deshmukh H, Kim-Howard X, Nath SK. Replication of recently identified
associated single-nucleotide polymorphisms from six autoimmune diseases
in Genetic Analysis Workshop 16 rheumatoid arthritis data. BMC Proc.
2009;3 Suppl 7:S31.
9. Lettre G, Rioux JD. Autoimmune diseases: insights from genome-wide association
studies. Hum Mol Genet. 2008;17(R2):R116–21.
10. Anaya J-M. The autoimmune tautology. Arthritis Res Ther. 2010;12(6):147.
11. Hafler JP, Maier LM, Cooper JD, Plagnol V, Hinks A, Simmonds MJ, et al.
CD226 Gly307Ser association with multiple autoimmune diseases. Genes
Immun. 2009;10(1):5–10.
12. Dieudé P, Guedj M, Truchetet ME, Wipff J, Revillod L, Riemekasten G, et al.
Association of the CD226 Ser(307) variant with systemic sclerosis: evidence
of a contribution of costimulation pathways in systemic sclerosis
pathogenesis. Arthritis Rheum. 2011;63(4):1097–105.
13. Maiti AK, Kim-Howard X, Viswanathan P, Guillén L, Qian X, Rojas-Villarraga A,
et al. Non-synonymous variant (Gly307Ser) in CD226 is associated with
susceptibility to multiple autoimmune diseases. Rheumatol Oxf Engl.
2010;49(7):1239–44.
14. Qiu Z-X, Zhang K, Qiu X-S, Zhou M, Li W-M. CD226 Gly307Ser association
with multiple autoimmune diseases: a meta-analysis. Hum Immunol.
2013;74(2):249–55.
15. Du Y, Shen L-X, Yu L-K, Song Y, Zhu J-F, Du R. The CD226 gene in susceptibility
of rheumatoid arthritis in the Chinese Han population. Rheumatol Int.
2012;32(5):1299–304.
16. Liu R, Xu N, Wang X, Shen L, Zhao G, Zhang H, et al. Influence of MIF, CD40,
and CD226 polymorphisms on risk of rheumatoid arthritis. Mol Biol Rep.
2012;39(6):6915–22.
17. Deshmukh HA, Maiti AK, Kim-Howard XR, Rojas-Villarraga A, Guthridge JM,
Anaya J-M, et al. Evaluation of 19 autoimmune disease-associated loci with
rheumatoid arthritis in a Colombian population: evidence for replication
and gene-gene interaction. J Rheumatol. 2011;38(9):1866–70.
18. Suzuki T, Ikari K, Kawaguchi Y, Yano K, Iwamoto T, Kawamoto M, et al.
Non-synonymous variant (Gly307Ser) in CD226 is associated with
susceptibility in Japanese rheumatoid arthritis patients. Mod Rheumatol
Jpn Rheum Assoc. 2013;23(1):200–2.
19. Shibuya A, Campbell D, Hannum C, Yssel H, Franz-Bacon K, McClanahan T,
et al. DNAM-1, a novel adhesion molecule involved in the cytolytic function
of T lymphocytes. Immunity. 1996;4(6):573‑81
20. Boissier M-C, Semerano L, Challal S, Saidenberg-Kermanac’h N, Falgarone G.
Rheumatoid arthritis: from autoimmunity to synovitis and joint destruction.
J Autoimmun. 2012;39(3):222–8.
21. Fasth AER, Björkström NK, Anthoni M, Malmberg K-J, Malmström V. Activating
NK-cell receptors co-stimulate CD4(+)CD28(-) T cells in patients with
rheumatoid arthritis. Eur J Immunol. 2010;40(2):378–87.
22. Myers LK, Rosloniec EF, Cremer MA, Kang AH. Collagen-induced arthritis, an
animal model of autoimmunity. Life Sci. 1997;61(19):1861–78.
23. Courtenay JS, Dallman MJ, Dayan AD, Martin A, Mosedale B. Immunisation
against heterologous type II collagen induces arthritis in mice. Nature.
1980;283(5748):666–8.
24. Durie FH, Fava RA, Noelle RJ. Collagen-induced arthritis as a model of
rheumatoid arthritis. Clin Immunol Immunopathol. 1994;73(1):11–8.
Elhai et al. Journal of Inflammation  (2015) 12:9 Page 12 of 1225. Gilfillan S, Chan CJ, Cella M, Haynes NM, Rapaport AS, Boles KS, et al. DNAM-1
promotes activation of cytotoxic lymphocytes by nonprofessional
antigen-presenting cells and tumors. J Exp Med. 2008;205(13):2965–73.
26. Guéry L, Batteux F, Bessis N, Breban M, Boissier MC, Fournier C, et al.
Expression of Fas ligand improves the effect of IL-4 in collagen-induced
arthritis. Eur J Immunol. 2000;30(1):308–15.
27. Inglis JJ, Criado G, Medghalchi M, Andrews M, Sandison A, Feldmann M, et al.
Collagen-induced arthritis in C57BL/6 mice is associated with a robust and
sustained T-cell response to type II collagen. Arthritis Res Ther. 2007;9(5):R113.
28. Campbell IK, Hamilton JA, Wicks IP. Collagen-induced arthritis in C57BL/6
(H-2b) mice: new insights into an important disease model of rheumatoid
arthritis. Eur J Immunol. 2000;30(6):1568–75.
29. Avouac J, Elhai M, Tomcik M, Ruiz B, Friese M, Piedavent M, et al. Critical
role of the adhesion receptor DNAX accessory molecule-1 (DNAM-1) in the
development of inflammation-driven dermal fibrosis in a mouse model of
systemic sclerosis. Ann Rheum Dis. 2013;72(6):1089–98.
30. Tahara-Hanaoka S, Shibuya K, Kai H, Miyamoto A, Morikawa Y, Ohkochi N,
et al. Tumor rejection by the poliovirus receptor family ligands of the
DNAM-1 (CD226) receptor. Blood. 2006;107(4):1491–6.
31. Yamashita Y, Abe F, Hirochika R, Tahara-Hanaoka S, Shibuya A, Shibuya K.
Establishment and characterization of a novel anti-DNAM-1 monoclonal
antibody. Monoclon Antib Immunodiagn Immunother. 2013;32(1):60–4.
doi: 10.1089/mab.2012.0083.
32. Glatigny S, Blaton M-A, Mencher SK, Mistou S, Lucas B, Fournier C, et al.
Treatment of collagen-induced arthritis by Natura-alpha via regulation of
Th-1/Th-17 responses. Eur J Immunol. 2010;40(2):460–9.
33. Elhai M, Jérôme A, Marchiol C, Renault G, Ruiz B, Fréchet M, et al.
Performance of skin ultrasound to measure skin involvement in different
animal models of systemic sclerosis. Ultrasound Med Biol. 2013;39(5):845–52.
34. Clavel G, Marchiol-Fournigault C, Renault G, Boissier M-C, Fradelizi D, Bessis N.
Ultrasound and Doppler micro-imaging in a model of rheumatoid arthritis in
mice. Ann Rheum Dis. 2008;67(12):1765–72.
35. Saidenberg-Kermanac’h N, Bessis N, Lemeiter D, de Vernejoul M-C, Boissier
M-C, Cohen-Solal M. Interleukin-4 cellular gene therapy and osteoprotegerin
decrease inflammation-associated bone resorption in collagen-induced
arthritis. J Clin Immunol. 2004;24(4):370–8.
36. Song G, Bae S-C, Choi S, Ji J, Lee Y. Association between the CD226
rs763361 polymorphism and susceptibility to autoimmune diseases: a
meta-analysis. Lupus. 2012;21(14):1522–30.
37. Gan EH, Mitchell AL, Macarthur K, Pearce SHS. The role of a nonsynonymous
CD226 (DNAX-accessory molecule-1) variant (Gly 307Ser) in isolated Addison’s
disease and autoimmune polyendocrinopathy type 2 pathogenesis. Clin
Endocrinol (Oxf). 2011;75(2):165–8.
38. Nabekura T, Shibuya K, Takenaka E, Kai H, Shibata K, Yamashita Y, et al.
Critical role of DNAX accessory molecule-1 (DNAM-1) in the development
of acute graft-versus-host disease in mice. Proc Natl Acad Sci U S A.
2010;107(43):18593–8.
39. Anaya J-M, Gómez L, Castiblanco J. Is there a common genetic basis for
autoimmune diseases? Clin Dev Immunol. 2006;13(2–4):185–95.
40. Dardalhon V, Schubart AS, Reddy J, Meyers JH, Monney L, Sabatos CA,
et al. CD226 is specifically expressed on the surface of Th1 cells and
regulates their expansion and effector functions. J Immunol Baltim Md
1950. 2005;175(3):1558–65.
41. Kai H, Shibuya K, Wang Y, Kameta H, Kameyama T, Tahara-Hanaoka S, et al. Critical
role of M. tuberculosis for dendritic cell maturation to induce collagen-induced
arthritis in H-2b background of C57BL/6 mice. Immunology. 2006;118(2):233–9.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
